Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1810404,exchange volume,"Mean exchange volume was 42.5 +/- 10.7 ml/kg BW (26.8-54.6 ml/kg), mean Hb dose 3.7 +/- 0.9 g PolyHb-PPa/kg BW (2.4-4.8 g/kg), mean exchange rate 56.7 +/- 7.1% (48.2-67.4%).",Elimination of pyridoxylated polyhemoglobin after partial exchange transfusion in chimpanzees. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810404/),[ml] / [kg],42.5,29345,DB00114,Pyridoxal Phosphate
,1810404,exchange rate,"Mean exchange volume was 42.5 +/- 10.7 ml/kg BW (26.8-54.6 ml/kg), mean Hb dose 3.7 +/- 0.9 g PolyHb-PPa/kg BW (2.4-4.8 g/kg), mean exchange rate 56.7 +/- 7.1% (48.2-67.4%).",Elimination of pyridoxylated polyhemoglobin after partial exchange transfusion in chimpanzees. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810404/),%,56.7,29346,DB00114,Pyridoxal Phosphate
,1810404,intravascular half-life,Mean intravascular half-life was 14.6 +/- 3.2 h.,Elimination of pyridoxylated polyhemoglobin after partial exchange transfusion in chimpanzees. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810404/),h,14.6,29347,DB00114,Pyridoxal Phosphate
,1810404,Total renal elimination,Total renal elimination of PolyHb-PPa was about 7%.,Elimination of pyridoxylated polyhemoglobin after partial exchange transfusion in chimpanzees. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810404/),%,7,29348,DB00114,Pyridoxal Phosphate
,1391506,plasma half-life,"Furthermore, the clearance of large polymers appeared to be highly dose-dependent: after 20% and 70% exchange transfusions, we observed for large polymers a plasma half-life of 12 and 26 hours, respectively, whereas the half-life for 64 kD monomers was 4 hours in both cases.",Effect of polymerization on clearance and degradation of free hemoglobin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391506/),h,12,38872,DB00114,Pyridoxal Phosphate
,1391506,plasma half-life,"Furthermore, the clearance of large polymers appeared to be highly dose-dependent: after 20% and 70% exchange transfusions, we observed for large polymers a plasma half-life of 12 and 26 hours, respectively, whereas the half-life for 64 kD monomers was 4 hours in both cases.",Effect of polymerization on clearance and degradation of free hemoglobin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391506/),h,26,38873,DB00114,Pyridoxal Phosphate
,1391506,half-life,"Furthermore, the clearance of large polymers appeared to be highly dose-dependent: after 20% and 70% exchange transfusions, we observed for large polymers a plasma half-life of 12 and 26 hours, respectively, whereas the half-life for 64 kD monomers was 4 hours in both cases.",Effect of polymerization on clearance and degradation of free hemoglobin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391506/),h,4,38874,DB00114,Pyridoxal Phosphate
,26316161,specific activity,"The specific activity of free-CGL and PEG-CGL was 59.71 and 48.71 U/mg, respectively, with a PEGylation yield of 81.5 and 70.7% modification of surface ε-amino groups.",Biochemical and Pharmacokinetic Properties of PEGylated Cystathionine γ-Lyase from Aspergillus carneus KF723837. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26316161/),[u] / [mg],59.71,41214,DB00114,Pyridoxal Phosphate
,26316161,specific activity,"The specific activity of free-CGL and PEG-CGL was 59.71 and 48.71 U/mg, respectively, with a PEGylation yield of 81.5 and 70.7% modification of surface ε-amino groups.",Biochemical and Pharmacokinetic Properties of PEGylated Cystathionine γ-Lyase from Aspergillus carneus KF723837. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26316161/),[u] / [mg],48.71,41215,DB00114,Pyridoxal Phosphate
,26316161,inhibition constant,"The inhibition constant values of propargylglycine were 0.31 and 0.52 µM for the free- and PEG-CGL, respectively.",Biochemical and Pharmacokinetic Properties of PEGylated Cystathionine γ-Lyase from Aspergillus carneus KF723837. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26316161/),μM,0.31,41216,DB00114,Pyridoxal Phosphate
,26316161,inhibition constant,"The inhibition constant values of propargylglycine were 0.31 and 0.52 µM for the free- and PEG-CGL, respectively.",Biochemical and Pharmacokinetic Properties of PEGylated Cystathionine γ-Lyase from Aspergillus carneus KF723837. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26316161/),μM,0.52,41217,DB00114,Pyridoxal Phosphate
,26316161,T1/2,"From in vivo pharmacokinetics in New Zealand white rabbits, the T1/2 was 19.1 and 28.9 h for the Holo free-CGL and PEG-CGL, respectively, ensuring the role of PEGylation on shielding the CGL surface from proteolytic attack, reducing its antigenicity, and stabilizing its internal Schiff base.",Biochemical and Pharmacokinetic Properties of PEGylated Cystathionine γ-Lyase from Aspergillus carneus KF723837. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26316161/),h,19.1,41218,DB00114,Pyridoxal Phosphate
,26316161,T1/2,"From in vivo pharmacokinetics in New Zealand white rabbits, the T1/2 was 19.1 and 28.9 h for the Holo free-CGL and PEG-CGL, respectively, ensuring the role of PEGylation on shielding the CGL surface from proteolytic attack, reducing its antigenicity, and stabilizing its internal Schiff base.",Biochemical and Pharmacokinetic Properties of PEGylated Cystathionine γ-Lyase from Aspergillus carneus KF723837. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26316161/),h,28.9,41219,DB00114,Pyridoxal Phosphate
,26316161,T1/2,"By external infusion of pyridoxal 5'-phosphate (10 µM), the T1/2 of free- and PEG-CGL was prolonged to 24 and 33 h, respectively, so dissociation of pyridoxal 5'-phosphate was one of the main causes of loss of enzyme activity.",Biochemical and Pharmacokinetic Properties of PEGylated Cystathionine γ-Lyase from Aspergillus carneus KF723837. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26316161/),h,24,41220,DB00114,Pyridoxal Phosphate
,26316161,T1/2,"By external infusion of pyridoxal 5'-phosphate (10 µM), the T1/2 of free- and PEG-CGL was prolonged to 24 and 33 h, respectively, so dissociation of pyridoxal 5'-phosphate was one of the main causes of loss of enzyme activity.",Biochemical and Pharmacokinetic Properties of PEGylated Cystathionine γ-Lyase from Aspergillus carneus KF723837. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26316161/),h,33,41221,DB00114,Pyridoxal Phosphate
,30725418,T1/2,Pharmacokinetic analysis showed that rMETase was eliminated with a T1/2 of 2.49 h.,Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in Primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725418/),h,2.49,44036,DB00114,Pyridoxal Phosphate
,30725418,biological half-life,"In pharmacokinetic studies, a single 4000 units/kg dose showed that MEGC-PEG-rMETase holoenzyme activity was eliminated with a biological half-life of 1.3 h, and the MEGC-PEG-rMETase apoenzyme was eliminated with a biological half-life of 90 h, a 36-fold increase compared with non-PEGylated rMETase.",Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in Primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725418/),h,1.3,44037,DB00114,Pyridoxal Phosphate
,30725418,biological half-life,"In pharmacokinetic studies, a single 4000 units/kg dose showed that MEGC-PEG-rMETase holoenzyme activity was eliminated with a biological half-life of 1.3 h, and the MEGC-PEG-rMETase apoenzyme was eliminated with a biological half-life of 90 h, a 36-fold increase compared with non-PEGylated rMETase.",Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in Primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725418/),h,90,44038,DB00114,Pyridoxal Phosphate
<,30725418,steady-state depletion,A 7-day i.v. administration of 4000 units/kg every 12 h resulted in a steady-state depletion of plasma MET to <5 μmol/L.,Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in Primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725418/),μmo,5,44039,DB00114,Pyridoxal Phosphate
,2730815,P50,"Hemoglobin (Hb) modified with an interdimeric bicovalent cross link using 2-nor-2-formylpyridoxal 5'-phosphate (NFPLP) as the cross-linking agent has an exceptionally low O2 affinity (P50 = 47 torr), enabling it to deliver more oxygen at tissue pO2 than blood.",Plasma retention and metabolic fate of hemoglobin modified with an interdimeric covalent cross link. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2730815/),torr,47,57351,DB00114,Pyridoxal Phosphate
,19834427,clearance,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),[l] / [h],23.1,59323,DB00114,Pyridoxal Phosphate
,19834427,central,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,35.4,59324,DB00114,Pyridoxal Phosphate
,19834427,peripheral volume of distribution,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,35.4,59325,DB00114,Pyridoxal Phosphate
,19834427,peripheral volume of distribution,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,1090,59326,DB00114,Pyridoxal Phosphate
,19834427,intercompartmental clearance,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,27.3,59327,DB00114,Pyridoxal Phosphate
,19834427,mean transit time (tau),"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),d,3.8,59328,DB00114,Pyridoxal Phosphate
,19834427,tau,"When patients had an early decrease in bilirubin at day 7, tau increased to 28.2 days.",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),d,28.2,59329,DB00114,Pyridoxal Phosphate
,3772225,half-disappearance times,"The half-disappearance times for HbNFPLP and Hb were found to be 3 hours and 1 hour in rats and 7 hours and 2.5 hours in rabbits, respectively.",Prolonged vascular retention of a hemoglobin solution modified by cross-linking with 2-nor-2-formylpyridoxal 5'-phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772225/),h,3,59938,DB00114,Pyridoxal Phosphate
,3772225,half-disappearance times,"The half-disappearance times for HbNFPLP and Hb were found to be 3 hours and 1 hour in rats and 7 hours and 2.5 hours in rabbits, respectively.",Prolonged vascular retention of a hemoglobin solution modified by cross-linking with 2-nor-2-formylpyridoxal 5'-phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772225/),h,1,59939,DB00114,Pyridoxal Phosphate
,3772225,half-disappearance times,"The half-disappearance times for HbNFPLP and Hb were found to be 3 hours and 1 hour in rats and 7 hours and 2.5 hours in rabbits, respectively.",Prolonged vascular retention of a hemoglobin solution modified by cross-linking with 2-nor-2-formylpyridoxal 5'-phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772225/),h,7,59940,DB00114,Pyridoxal Phosphate
,3772225,half-disappearance times,"The half-disappearance times for HbNFPLP and Hb were found to be 3 hours and 1 hour in rats and 7 hours and 2.5 hours in rabbits, respectively.",Prolonged vascular retention of a hemoglobin solution modified by cross-linking with 2-nor-2-formylpyridoxal 5'-phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772225/),h,2.5,59941,DB00114,Pyridoxal Phosphate
,1530676,maximum plasma concentration,"1.5 h) reaching the maximum plasma concentration, which was about 467 ng/ml, in about 3 h.",Pharmacokinetics of a sustained release formulation of pyridoxal phosphate of buflomedil after single or repeated oral doses in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530676/),[ng] / [ml],467,89704,DB00114,Pyridoxal Phosphate
,1530676,steady state plasma levels,Repeated administration of the SR formulation for 7 days in single daily doses of 400 mg gave steady state plasma levels (ca. 250 ng/ml) 12 h after the administration without statistically significant variations.,Pharmacokinetics of a sustained release formulation of pyridoxal phosphate of buflomedil after single or repeated oral doses in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530676/),[ng] / [ml],250,89705,DB00114,Pyridoxal Phosphate
,12083775,half-life,"The effectiveness of PET as a diagnostic tool, the convenient half-life of (18)F (110 min) and the favorable pharmacokinetics of 6-[(18)F]FDOPA have combined to make this an extremely valuable reagent to study dopaminergic activity.","Behavior of fluorinated analogs of L-(3,4-dihydroxyphenyl)alanine and L-threo-(3,4-dihydroxyphenyl)serine as substrates for Dopa decarboxylase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083775/),min,110,95910,DB00114,Pyridoxal Phosphate
,15313919,half-life,Pumps containing 500 mg/ml PLP increased the half-life of MEGC-PEG-rMETase holoenzyme 4.5-fold from 1.5 to 7 h.,Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15313919/),h,1.5,96671,DB00114,Pyridoxal Phosphate
,15313919,half-life,Pumps containing 500 mg/ml PLP increased the half-life of MEGC-PEG-rMETase holoenzyme 4.5-fold from 1.5 to 7 h.,Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15313919/),h,7,96672,DB00114,Pyridoxal Phosphate
,23444286,apparent CL,"There was no difference in the apparent CL of doxylamine in women in their first trimester of pregnancy when compared with nonpregnant women on day 4 (median = 196.7 vs 249.5 mL/h/kg, respectively, P = .065), day 8 (median = 248.4 vs 249.5 mL/h/kg, respectively, P = .82), and day 15 (median = 200.9 vs 249.5 mL/h/kg, respectively, P = .55).",Comparing the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in nonpregnant women of reproductive age and women in the first trimester of pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444286/),[ml] / [h·kg],196.7,107131,DB00114,Pyridoxal Phosphate
,23444286,apparent CL,"There was no difference in the apparent CL of doxylamine in women in their first trimester of pregnancy when compared with nonpregnant women on day 4 (median = 196.7 vs 249.5 mL/h/kg, respectively, P = .065), day 8 (median = 248.4 vs 249.5 mL/h/kg, respectively, P = .82), and day 15 (median = 200.9 vs 249.5 mL/h/kg, respectively, P = .55).",Comparing the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in nonpregnant women of reproductive age and women in the first trimester of pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444286/),[ml] / [h·kg],249.5,107132,DB00114,Pyridoxal Phosphate
,23444286,apparent CL,"There was no difference in the apparent CL of doxylamine in women in their first trimester of pregnancy when compared with nonpregnant women on day 4 (median = 196.7 vs 249.5 mL/h/kg, respectively, P = .065), day 8 (median = 248.4 vs 249.5 mL/h/kg, respectively, P = .82), and day 15 (median = 200.9 vs 249.5 mL/h/kg, respectively, P = .55).",Comparing the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in nonpregnant women of reproductive age and women in the first trimester of pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444286/),[ml] / [h·kg],248.4,107133,DB00114,Pyridoxal Phosphate
,23444286,apparent CL,"There was no difference in the apparent CL of doxylamine in women in their first trimester of pregnancy when compared with nonpregnant women on day 4 (median = 196.7 vs 249.5 mL/h/kg, respectively, P = .065), day 8 (median = 248.4 vs 249.5 mL/h/kg, respectively, P = .82), and day 15 (median = 200.9 vs 249.5 mL/h/kg, respectively, P = .55).",Comparing the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in nonpregnant women of reproductive age and women in the first trimester of pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444286/),[ml] / [h·kg],200.9,107134,DB00114,Pyridoxal Phosphate
,23444286,apparent CL,"No difference was found in the apparent CL of PLP on day 15 (median = 342.3 vs 314.7 mL/h/kg, respectively, P = .92).",Comparing the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in nonpregnant women of reproductive age and women in the first trimester of pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444286/),[ml] / [h·kg],342.3,107135,DB00114,Pyridoxal Phosphate
,23444286,apparent CL,"No difference was found in the apparent CL of PLP on day 15 (median = 342.3 vs 314.7 mL/h/kg, respectively, P = .92).",Comparing the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in nonpregnant women of reproductive age and women in the first trimester of pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444286/),[ml] / [h·kg],314.7,107136,DB00114,Pyridoxal Phosphate
,22432561,T(max),"Total CoQ(10) (T(max)) reached maximum plasma concentrations at 6.4 ± 2.5 hr after supplementation with CoQ(10) (NPN 02176955), 8.0 ± 9.8 hr with CoQ(10)-P5P-PC, and 9.5 ± 9.3 hr with CoQ(10) (DIN 02231736).","A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22432561/),h,6.4,110285,DB00114,Pyridoxal Phosphate
,22432561,T(max),"Total CoQ(10) (T(max)) reached maximum plasma concentrations at 6.4 ± 2.5 hr after supplementation with CoQ(10) (NPN 02176955), 8.0 ± 9.8 hr with CoQ(10)-P5P-PC, and 9.5 ± 9.3 hr with CoQ(10) (DIN 02231736).","A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22432561/),h,8.0,110286,DB00114,Pyridoxal Phosphate
,22432561,T(max),"Total CoQ(10) (T(max)) reached maximum plasma concentrations at 6.4 ± 2.5 hr after supplementation with CoQ(10) (NPN 02176955), 8.0 ± 9.8 hr with CoQ(10)-P5P-PC, and 9.5 ± 9.3 hr with CoQ(10) (DIN 02231736).","A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22432561/),h,9.5,110287,DB00114,Pyridoxal Phosphate
,22432561,elimination half-life (t(1/2)),"The estimated elimination half-life (t(1/2)) was 92.3 hr after a single oral dose of CoQ(10)-P5P-PC, 38.2 hr with CoQ(10) (NPN 02176955), and 80.7 hr with CoQ(10) (DIN 02231736).","A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22432561/),h,92.3,110288,DB00114,Pyridoxal Phosphate
,22432561,elimination half-life (t(1/2)),"The estimated elimination half-life (t(1/2)) was 92.3 hr after a single oral dose of CoQ(10)-P5P-PC, 38.2 hr with CoQ(10) (NPN 02176955), and 80.7 hr with CoQ(10) (DIN 02231736).","A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22432561/),h,38.2,110289,DB00114,Pyridoxal Phosphate
,22432561,elimination half-life (t(1/2)),"The estimated elimination half-life (t(1/2)) was 92.3 hr after a single oral dose of CoQ(10)-P5P-PC, 38.2 hr with CoQ(10) (NPN 02176955), and 80.7 hr with CoQ(10) (DIN 02231736).","A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22432561/),h,80.7,110290,DB00114,Pyridoxal Phosphate
,992265,clearance,"The initial and steady state volumes of distribution of PLP were comparable in cirrhotics and controls (P greater than 0.05), but the clearance of plasma PLP in cirrhotics was much faster (63.0 +/- 7.4 versus 31.7 +/- 2.7 ml per min, P less than 0.004).",Abnormal regulation of plasma pyridoxal 5'-phosphate in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/992265/),[ml] / [min],63.0,123585,DB00114,Pyridoxal Phosphate
,992265,clearance,"The initial and steady state volumes of distribution of PLP were comparable in cirrhotics and controls (P greater than 0.05), but the clearance of plasma PLP in cirrhotics was much faster (63.0 +/- 7.4 versus 31.7 +/- 2.7 ml per min, P less than 0.004).",Abnormal regulation of plasma pyridoxal 5'-phosphate in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/992265/),[ml] / [min],31.7,123586,DB00114,Pyridoxal Phosphate
,992265,plasma binding,"The in vitro plasma binding of PLP at supracirculatory concentrations was comparable in cirrhotics and controls (99.4 versus 99.5%, P greater than 0.05).",Abnormal regulation of plasma pyridoxal 5'-phosphate in patients with liver disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/992265/),%,99.4,123587,DB00114,Pyridoxal Phosphate
,992265,plasma binding,"The in vitro plasma binding of PLP at supracirculatory concentrations was comparable in cirrhotics and controls (99.4 versus 99.5%, P greater than 0.05).",Abnormal regulation of plasma pyridoxal 5'-phosphate in patients with liver disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/992265/),%,99.5,123588,DB00114,Pyridoxal Phosphate
<,28544589,half-life,MGL half-life was increased from <24 h to 9-12 days when encapsulated in RBC.,Methionine tumor starvation by erythrocyte-encapsulated methionine gamma-lyase activity controlled with per os vitamin B6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544589/),h,24,141633,DB00114,Pyridoxal Phosphate
,28544589,half-life,MGL half-life was increased from <24 h to 9-12 days when encapsulated in RBC.,Methionine tumor starvation by erythrocyte-encapsulated methionine gamma-lyase activity controlled with per os vitamin B6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544589/),d,9-12,141634,DB00114,Pyridoxal Phosphate
,2925164,percentage excretion,"The data indicated that supplementation achieved repletion of peripheral B6 stores, as evidenced by: (i) a significant (p less than 0.005) rise in fasting plasma pyridoxal phosphate after supplementation (mean +/- S.D. = 56.8 +/- 30.5 nmoles per liter) as compared to initial levels (17.0 +/- 17.8 nmoles per liter); (ii) a higher (p less than 0.05) percentage excretion of the pyridoxine load as urinary 4-pyridoxic acid (31.0 +/- 9.3%) compared to the initial load (19.6 +/- 5.8%), and (iii) a postsupplementation area under the plasma concentration vs. time curve for pyridoxal phosphate (377 +/- 529 nmoles.hr per liter), which was decreased (p less than 0.005) from the presupplementation value (934 +/- 756 nmoles.hr per liter).",Vitamin B6 repletion in cirrhosis with oral pyridoxine: failure to improve amino acid metabolism. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2925164/),,31,155954,DB00114,Pyridoxal Phosphate
,2925164,percentage excretion,"The data indicated that supplementation achieved repletion of peripheral B6 stores, as evidenced by: (i) a significant (p less than 0.005) rise in fasting plasma pyridoxal phosphate after supplementation (mean +/- S.D. = 56.8 +/- 30.5 nmoles per liter) as compared to initial levels (17.0 +/- 17.8 nmoles per liter); (ii) a higher (p less than 0.05) percentage excretion of the pyridoxine load as urinary 4-pyridoxic acid (31.0 +/- 9.3%) compared to the initial load (19.6 +/- 5.8%), and (iii) a postsupplementation area under the plasma concentration vs. time curve for pyridoxal phosphate (377 +/- 529 nmoles.hr per liter), which was decreased (p less than 0.005) from the presupplementation value (934 +/- 756 nmoles.hr per liter).",Vitamin B6 repletion in cirrhosis with oral pyridoxine: failure to improve amino acid metabolism. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2925164/),,19,155955,DB00114,Pyridoxal Phosphate
,2925164,area under the plasma concentration vs. time curve,"The data indicated that supplementation achieved repletion of peripheral B6 stores, as evidenced by: (i) a significant (p less than 0.005) rise in fasting plasma pyridoxal phosphate after supplementation (mean +/- S.D. = 56.8 +/- 30.5 nmoles per liter) as compared to initial levels (17.0 +/- 17.8 nmoles per liter); (ii) a higher (p less than 0.05) percentage excretion of the pyridoxine load as urinary 4-pyridoxic acid (31.0 +/- 9.3%) compared to the initial load (19.6 +/- 5.8%), and (iii) a postsupplementation area under the plasma concentration vs. time curve for pyridoxal phosphate (377 +/- 529 nmoles.hr per liter), which was decreased (p less than 0.005) from the presupplementation value (934 +/- 756 nmoles.hr per liter).",Vitamin B6 repletion in cirrhosis with oral pyridoxine: failure to improve amino acid metabolism. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2925164/),[h·nmoles] / [l],377,155956,DB00114,Pyridoxal Phosphate
,2925164,area under the plasma concentration vs. time curve,"The data indicated that supplementation achieved repletion of peripheral B6 stores, as evidenced by: (i) a significant (p less than 0.005) rise in fasting plasma pyridoxal phosphate after supplementation (mean +/- S.D. = 56.8 +/- 30.5 nmoles per liter) as compared to initial levels (17.0 +/- 17.8 nmoles per liter); (ii) a higher (p less than 0.05) percentage excretion of the pyridoxine load as urinary 4-pyridoxic acid (31.0 +/- 9.3%) compared to the initial load (19.6 +/- 5.8%), and (iii) a postsupplementation area under the plasma concentration vs. time curve for pyridoxal phosphate (377 +/- 529 nmoles.hr per liter), which was decreased (p less than 0.005) from the presupplementation value (934 +/- 756 nmoles.hr per liter).",Vitamin B6 repletion in cirrhosis with oral pyridoxine: failure to improve amino acid metabolism. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2925164/),[h·nmoles] / [l],934,155957,DB00114,Pyridoxal Phosphate
,8229700,limit of detection,The limit of detection was 2 ng/mL and interday variation (3 days) over the whole concentration range (13-215 ng/mL spiked) was < 4.1%.,Determination of total pyridoxal in human plasma following oral administration of vitamin B6 by high-performance liquid chromatography with post-column derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229700/),[ng] / [ml],2,171342,DB00114,Pyridoxal Phosphate
,8229700,Total endogenous pyridoxal,Total endogenous pyridoxal detected on the 2nd day varied in plasma between 13 and 17 ng/mL.,Determination of total pyridoxal in human plasma following oral administration of vitamin B6 by high-performance liquid chromatography with post-column derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229700/),[ng] / [ml],13 and 17,171343,DB00114,Pyridoxal Phosphate
,8229700,AUC0-24,"Briefly, the pharmacokinetic results for the Ratiopharm preparation compared with the Hoffmann-La Roche preparation are, respectively: AUC0-24, 369.2 and 352.6 ng.h/mL; AUC24-48, 1638.2 and 1662.3 ng.h/mL; net Cmax, 193.0 and 197.1 ng/mL; tmax, 1.25 and 1.44 h; and relative bioavailability, 97.9% (Westlake, 88-112%).",Determination of total pyridoxal in human plasma following oral administration of vitamin B6 by high-performance liquid chromatography with post-column derivatization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229700/),[h·ng] / [ml],369.2,171344,DB00114,Pyridoxal Phosphate
,8229700,AUC0-24,"Briefly, the pharmacokinetic results for the Ratiopharm preparation compared with the Hoffmann-La Roche preparation are, respectively: AUC0-24, 369.2 and 352.6 ng.h/mL; AUC24-48, 1638.2 and 1662.3 ng.h/mL; net Cmax, 193.0 and 197.1 ng/mL; tmax, 1.25 and 1.44 h; and relative bioavailability, 97.9% (Westlake, 88-112%).",Determination of total pyridoxal in human plasma following oral administration of vitamin B6 by high-performance liquid chromatography with post-column derivatization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229700/),[h·ng] / [ml],352.6,171345,DB00114,Pyridoxal Phosphate
,8229700,AUC24-48,"Briefly, the pharmacokinetic results for the Ratiopharm preparation compared with the Hoffmann-La Roche preparation are, respectively: AUC0-24, 369.2 and 352.6 ng.h/mL; AUC24-48, 1638.2 and 1662.3 ng.h/mL; net Cmax, 193.0 and 197.1 ng/mL; tmax, 1.25 and 1.44 h; and relative bioavailability, 97.9% (Westlake, 88-112%).",Determination of total pyridoxal in human plasma following oral administration of vitamin B6 by high-performance liquid chromatography with post-column derivatization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229700/),[h·ng] / [ml],1638.2,171346,DB00114,Pyridoxal Phosphate
,8229700,AUC24-48,"Briefly, the pharmacokinetic results for the Ratiopharm preparation compared with the Hoffmann-La Roche preparation are, respectively: AUC0-24, 369.2 and 352.6 ng.h/mL; AUC24-48, 1638.2 and 1662.3 ng.h/mL; net Cmax, 193.0 and 197.1 ng/mL; tmax, 1.25 and 1.44 h; and relative bioavailability, 97.9% (Westlake, 88-112%).",Determination of total pyridoxal in human plasma following oral administration of vitamin B6 by high-performance liquid chromatography with post-column derivatization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229700/),[h·ng] / [ml],1662.3,171347,DB00114,Pyridoxal Phosphate
,8229700,net Cmax,"Briefly, the pharmacokinetic results for the Ratiopharm preparation compared with the Hoffmann-La Roche preparation are, respectively: AUC0-24, 369.2 and 352.6 ng.h/mL; AUC24-48, 1638.2 and 1662.3 ng.h/mL; net Cmax, 193.0 and 197.1 ng/mL; tmax, 1.25 and 1.44 h; and relative bioavailability, 97.9% (Westlake, 88-112%).",Determination of total pyridoxal in human plasma following oral administration of vitamin B6 by high-performance liquid chromatography with post-column derivatization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229700/),[ng] / [ml],193.0,171348,DB00114,Pyridoxal Phosphate
,8229700,net Cmax,"Briefly, the pharmacokinetic results for the Ratiopharm preparation compared with the Hoffmann-La Roche preparation are, respectively: AUC0-24, 369.2 and 352.6 ng.h/mL; AUC24-48, 1638.2 and 1662.3 ng.h/mL; net Cmax, 193.0 and 197.1 ng/mL; tmax, 1.25 and 1.44 h; and relative bioavailability, 97.9% (Westlake, 88-112%).",Determination of total pyridoxal in human plasma following oral administration of vitamin B6 by high-performance liquid chromatography with post-column derivatization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229700/),[ng] / [ml],197.1,171349,DB00114,Pyridoxal Phosphate
,8229700,tmax,"Briefly, the pharmacokinetic results for the Ratiopharm preparation compared with the Hoffmann-La Roche preparation are, respectively: AUC0-24, 369.2 and 352.6 ng.h/mL; AUC24-48, 1638.2 and 1662.3 ng.h/mL; net Cmax, 193.0 and 197.1 ng/mL; tmax, 1.25 and 1.44 h; and relative bioavailability, 97.9% (Westlake, 88-112%).",Determination of total pyridoxal in human plasma following oral administration of vitamin B6 by high-performance liquid chromatography with post-column derivatization. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229700/),h,1.25,171350,DB00114,Pyridoxal Phosphate
,8229700,tmax,"Briefly, the pharmacokinetic results for the Ratiopharm preparation compared with the Hoffmann-La Roche preparation are, respectively: AUC0-24, 369.2 and 352.6 ng.h/mL; AUC24-48, 1638.2 and 1662.3 ng.h/mL; net Cmax, 193.0 and 197.1 ng/mL; tmax, 1.25 and 1.44 h; and relative bioavailability, 97.9% (Westlake, 88-112%).",Determination of total pyridoxal in human plasma following oral administration of vitamin B6 by high-performance liquid chromatography with post-column derivatization. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229700/),h,1.44,171351,DB00114,Pyridoxal Phosphate
,8229700,relative bioavailability,"Briefly, the pharmacokinetic results for the Ratiopharm preparation compared with the Hoffmann-La Roche preparation are, respectively: AUC0-24, 369.2 and 352.6 ng.h/mL; AUC24-48, 1638.2 and 1662.3 ng.h/mL; net Cmax, 193.0 and 197.1 ng/mL; tmax, 1.25 and 1.44 h; and relative bioavailability, 97.9% (Westlake, 88-112%).",Determination of total pyridoxal in human plasma following oral administration of vitamin B6 by high-performance liquid chromatography with post-column derivatization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229700/),%,97.9,171352,DB00114,Pyridoxal Phosphate
,8229700,relative bioavailability,"Briefly, the pharmacokinetic results for the Ratiopharm preparation compared with the Hoffmann-La Roche preparation are, respectively: AUC0-24, 369.2 and 352.6 ng.h/mL; AUC24-48, 1638.2 and 1662.3 ng.h/mL; net Cmax, 193.0 and 197.1 ng/mL; tmax, 1.25 and 1.44 h; and relative bioavailability, 97.9% (Westlake, 88-112%).",Determination of total pyridoxal in human plasma following oral administration of vitamin B6 by high-performance liquid chromatography with post-column derivatization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229700/),%,88-112,171353,DB00114,Pyridoxal Phosphate
,21079545,AUC0→∞,"The mean DOX-AUC0→∞ was calculated to be 3137.22 ± 633.57 ng·hr/mL (range, 2056.59-4376.06 ng·hr/mL).",Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079545/),[h·ng] / [ml],3137.22,172494,DB00114,Pyridoxal Phosphate
,21079545,AUC0→∞,"The mean PLP-AUC0→∞ was calculated to be 5513.10 ± 2362.35 ng·hr/mL (range, 1572.56-10,153.77 ng·hr/mL).",Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079545/),[h·ng] / [ml],5513.10,172495,DB00114,Pyridoxal Phosphate
,21079545,relative bioavailability,"Based on literature values of the PLP-AUC0→∞ after intravenous administration and data from the current study, the relative bioavailability of pyridoxine in Diclectin was calculated at 100%.",Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079545/),%,100,172496,DB00114,Pyridoxal Phosphate
,21079545,oral bioavailability,"Using literature values and data from the current study, we estimated the oral bioavailability of pyridoxine to be 100%.",Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079545/),%,100,172497,DB00114,Pyridoxal Phosphate
,24123059,AUC0-t,"Females had significantly larger AUC0-t for doxylamine, 1,550 ng h/mL (coefficient of variance [CV = 19%]) versus 1,272 ng h/mL (CV = 21%; P ≤ .05), and pyridoxine, 35 ng h/mL, (CV = 43%) versus 25 ng h/mL (CV = 31%; P ≤ .05) compared to males.",Sex differences in the pharmacokinetics and bioequivalence of the delayed-release combination of doxylamine succinate-pyridoxine hydrochloride; implications for pharmacotherapy in pregnancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123059/),[h·ng] / [ml],"1,550",179060,DB00114,Pyridoxal Phosphate
,24123059,AUC0-t,"Females had significantly larger AUC0-t for doxylamine, 1,550 ng h/mL (coefficient of variance [CV = 19%]) versus 1,272 ng h/mL (CV = 21%; P ≤ .05), and pyridoxine, 35 ng h/mL, (CV = 43%) versus 25 ng h/mL (CV = 31%; P ≤ .05) compared to males.",Sex differences in the pharmacokinetics and bioequivalence of the delayed-release combination of doxylamine succinate-pyridoxine hydrochloride; implications for pharmacotherapy in pregnancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123059/),[h·ng] / [ml],"1,272",179061,DB00114,Pyridoxal Phosphate
,24123059,AUC0-t,"Females had significantly larger AUC0-t for doxylamine, 1,550 ng h/mL (coefficient of variance [CV = 19%]) versus 1,272 ng h/mL (CV = 21%; P ≤ .05), and pyridoxine, 35 ng h/mL, (CV = 43%) versus 25 ng h/mL (CV = 31%; P ≤ .05) compared to males.",Sex differences in the pharmacokinetics and bioequivalence of the delayed-release combination of doxylamine succinate-pyridoxine hydrochloride; implications for pharmacotherapy in pregnancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123059/),[h·ng] / [ml],35,179062,DB00114,Pyridoxal Phosphate
,24123059,AUC0-t,"Females had significantly larger AUC0-t for doxylamine, 1,550 ng h/mL (coefficient of variance [CV = 19%]) versus 1,272 ng h/mL (CV = 21%; P ≤ .05), and pyridoxine, 35 ng h/mL, (CV = 43%) versus 25 ng h/mL (CV = 31%; P ≤ .05) compared to males.",Sex differences in the pharmacokinetics and bioequivalence of the delayed-release combination of doxylamine succinate-pyridoxine hydrochloride; implications for pharmacotherapy in pregnancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123059/),[h·ng] / [ml],25,179063,DB00114,Pyridoxal Phosphate
,24123059,Cmax,"A higher Cmax for doxylamine was observed in females, 107 ng/mL (CV = 16%), compared to males, 86 ng/mL (CV = 15%) (P ≤ .05).",Sex differences in the pharmacokinetics and bioequivalence of the delayed-release combination of doxylamine succinate-pyridoxine hydrochloride; implications for pharmacotherapy in pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123059/),[ng] / [ml],107,179064,DB00114,Pyridoxal Phosphate
,24123059,Cmax,"A higher Cmax for doxylamine was observed in females, 107 ng/mL (CV = 16%), compared to males, 86 ng/mL (CV = 15%) (P ≤ .05).",Sex differences in the pharmacokinetics and bioequivalence of the delayed-release combination of doxylamine succinate-pyridoxine hydrochloride; implications for pharmacotherapy in pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123059/),[ng] / [ml],86,179065,DB00114,Pyridoxal Phosphate
less,9245964,elimination half-life,"The manganese (Mn) moiety is rapidly removed from plasma with an elimination half-life of less than 25 min in both species, reflecting a rapid distribution to the tissues and an early excretion.","Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9245964/),min,25,184521,DB00114,Pyridoxal Phosphate
,10416911,effluent rate,A total of ten critically ill patients in oligoanuric acute renal failure (five treated by continuous venovenous hemofiltration and five by continuous venovenous hemodiafiltration) with a mean effluent rate of 1801 +/- 468 ml/h.,Serum concentrations and clearances of folic acid and pyridoxal-5-phosphate during venovenous continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10416911/),[ml] / [h],1801,188777,DB00114,Pyridoxal Phosphate
,10416911,clearances,"During CRRT, mean (+/- SEM) folic acid and P-5'-P clearances were 20.5 +/- 6.3 ml/min (n = 34) and 13.2 +/- 10.6 ml/min (n = 22), whereas mean urea clearance was 27.1 +/- 5.1 ml/min (n = 26).",Serum concentrations and clearances of folic acid and pyridoxal-5-phosphate during venovenous continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10416911/),[ml] / [min],13.2,188778,DB00114,Pyridoxal Phosphate
,10416911,urea clearance,"During CRRT, mean (+/- SEM) folic acid and P-5'-P clearances were 20.5 +/- 6.3 ml/min (n = 34) and 13.2 +/- 10.6 ml/min (n = 22), whereas mean urea clearance was 27.1 +/- 5.1 ml/min (n = 26).",Serum concentrations and clearances of folic acid and pyridoxal-5-phosphate during venovenous continuous renal replacement therapy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10416911/),[ml] / [min],27.1,188779,DB00114,Pyridoxal Phosphate
,10416911,removal rates,"Folic acid and P-5'-P removal rates were 27.0 +/- 34.2 and 3.4 +/- 2.0 nmol/h, corresponding to mean daily losses of nearly 650 and 80 nmol/day respectively.",Serum concentrations and clearances of folic acid and pyridoxal-5-phosphate during venovenous continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10416911/),[nM] / [h],27.0,188780,DB00114,Pyridoxal Phosphate
,10416911,removal rates,"Folic acid and P-5'-P removal rates were 27.0 +/- 34.2 and 3.4 +/- 2.0 nmol/h, corresponding to mean daily losses of nearly 650 and 80 nmol/day respectively.",Serum concentrations and clearances of folic acid and pyridoxal-5-phosphate during venovenous continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10416911/),[nM] / [h],3.4,188781,DB00114,Pyridoxal Phosphate
,1941181,Basal plasma PLP concentration,"Basal plasma PLP concentration was lower in both the less than 0.5 and 3 mg/kg diet groups than in control animals (98 +/- 12, 314 +/- 40 and 514 +/- 56 nmol/L, respectively).",Pyridoxal-5'-phosphate and pyridoxal biokinetics in male Wistar rats fed graded levels of vitamin B-6. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941181/),[nM] / [l],98,199839,DB00114,Pyridoxal Phosphate
,1941181,Basal plasma PLP concentration,"Basal plasma PLP concentration was lower in both the less than 0.5 and 3 mg/kg diet groups than in control animals (98 +/- 12, 314 +/- 40 and 514 +/- 56 nmol/L, respectively).",Pyridoxal-5'-phosphate and pyridoxal biokinetics in male Wistar rats fed graded levels of vitamin B-6. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941181/),[nM] / [l],314,199840,DB00114,Pyridoxal Phosphate
,1941181,Basal plasma PLP concentration,"Basal plasma PLP concentration was lower in both the less than 0.5 and 3 mg/kg diet groups than in control animals (98 +/- 12, 314 +/- 40 and 514 +/- 56 nmol/L, respectively).",Pyridoxal-5'-phosphate and pyridoxal biokinetics in male Wistar rats fed graded levels of vitamin B-6. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941181/),[nM] / [l],514,199841,DB00114,Pyridoxal Phosphate
,1941181,Basal plasma PL concentration,"Basal plasma PL concentration was lower in the less than 0.5 mg/kg diet group only [60 nmol/L (measured in pooled samples), 190 +/- 73 and 235 +/- 63 nmol/L for less than 0.5, 3 and 6 mg/kg diet groups, respectively].",Pyridoxal-5'-phosphate and pyridoxal biokinetics in male Wistar rats fed graded levels of vitamin B-6. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941181/),[nM] / [l],60,199842,DB00114,Pyridoxal Phosphate
,1941181,Basal plasma PL concentration,"Basal plasma PL concentration was lower in the less than 0.5 mg/kg diet group only [60 nmol/L (measured in pooled samples), 190 +/- 73 and 235 +/- 63 nmol/L for less than 0.5, 3 and 6 mg/kg diet groups, respectively].",Pyridoxal-5'-phosphate and pyridoxal biokinetics in male Wistar rats fed graded levels of vitamin B-6. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941181/),[nM] / [l],190,199843,DB00114,Pyridoxal Phosphate
,1941181,Basal plasma PL concentration,"Basal plasma PL concentration was lower in the less than 0.5 mg/kg diet group only [60 nmol/L (measured in pooled samples), 190 +/- 73 and 235 +/- 63 nmol/L for less than 0.5, 3 and 6 mg/kg diet groups, respectively].",Pyridoxal-5'-phosphate and pyridoxal biokinetics in male Wistar rats fed graded levels of vitamin B-6. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941181/),[nM] / [l],235,199844,DB00114,Pyridoxal Phosphate
,1941181,clearance,"In both the less than 0.5 and 3 mg/kg diet groups, PLP clearance was lower than in control rats (0.158 +/- 0.025, 0.131 +/- 0.040 and 0.240 +/- 0.051 L.h-1.kg body weight-1, respectively).",Pyridoxal-5'-phosphate and pyridoxal biokinetics in male Wistar rats fed graded levels of vitamin B-6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941181/),[body·kg·l] / [h·weight],0.158,199845,DB00114,Pyridoxal Phosphate
,1941181,clearance,"In both the less than 0.5 and 3 mg/kg diet groups, PLP clearance was lower than in control rats (0.158 +/- 0.025, 0.131 +/- 0.040 and 0.240 +/- 0.051 L.h-1.kg body weight-1, respectively).",Pyridoxal-5'-phosphate and pyridoxal biokinetics in male Wistar rats fed graded levels of vitamin B-6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941181/),[body·kg·l] / [h·weight],0.131,199846,DB00114,Pyridoxal Phosphate
,1941181,clearance,"In both the less than 0.5 and 3 mg/kg diet groups, PLP clearance was lower than in control rats (0.158 +/- 0.025, 0.131 +/- 0.040 and 0.240 +/- 0.051 L.h-1.kg body weight-1, respectively).",Pyridoxal-5'-phosphate and pyridoxal biokinetics in male Wistar rats fed graded levels of vitamin B-6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941181/),[body·kg·l] / [h·weight],0.240,199847,DB00114,Pyridoxal Phosphate
,1732480,T1/2,"In the pigs, [14C] removal was monophasic with T1/2 of 16 and 18 min and clearance of 165 and 248 mL/min.",Metabolism of [14C]- and [32P]pyridoxal 5'-phosphate and [3H]pyridoxal administered intravenously to pigs and goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732480/),min,16,241929,DB00114,Pyridoxal Phosphate
,1732480,T1/2,"In the pigs, [14C] removal was monophasic with T1/2 of 16 and 18 min and clearance of 165 and 248 mL/min.",Metabolism of [14C]- and [32P]pyridoxal 5'-phosphate and [3H]pyridoxal administered intravenously to pigs and goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732480/),min,18,241930,DB00114,Pyridoxal Phosphate
,1732480,clearance,"In the pigs, [14C] removal was monophasic with T1/2 of 16 and 18 min and clearance of 165 and 248 mL/min.",Metabolism of [14C]- and [32P]pyridoxal 5'-phosphate and [3H]pyridoxal administered intravenously to pigs and goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732480/),[ml] / [min],165,241931,DB00114,Pyridoxal Phosphate
,1732480,clearance,"In the pigs, [14C] removal was monophasic with T1/2 of 16 and 18 min and clearance of 165 and 248 mL/min.",Metabolism of [14C]- and [32P]pyridoxal 5'-phosphate and [3H]pyridoxal administered intravenously to pigs and goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732480/),[ml] / [min],248,241932,DB00114,Pyridoxal Phosphate
,1732480,T1/2,"In the goats, [14C] removal was biphasic with T1/2 of 49 and 114 min for 0-30 min and 209 and 227 min for 0.5-6 h (clearance 20 and 17 mL/min).",Metabolism of [14C]- and [32P]pyridoxal 5'-phosphate and [3H]pyridoxal administered intravenously to pigs and goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732480/),min,49,241933,DB00114,Pyridoxal Phosphate
,1732480,T1/2,"In the goats, [14C] removal was biphasic with T1/2 of 49 and 114 min for 0-30 min and 209 and 227 min for 0.5-6 h (clearance 20 and 17 mL/min).",Metabolism of [14C]- and [32P]pyridoxal 5'-phosphate and [3H]pyridoxal administered intravenously to pigs and goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732480/),min,114,241934,DB00114,Pyridoxal Phosphate
,1732480,T1/2,"In the goats, [14C] removal was biphasic with T1/2 of 49 and 114 min for 0-30 min and 209 and 227 min for 0.5-6 h (clearance 20 and 17 mL/min).",Metabolism of [14C]- and [32P]pyridoxal 5'-phosphate and [3H]pyridoxal administered intravenously to pigs and goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732480/),min,209,241935,DB00114,Pyridoxal Phosphate
,1732480,T1/2,"In the goats, [14C] removal was biphasic with T1/2 of 49 and 114 min for 0-30 min and 209 and 227 min for 0.5-6 h (clearance 20 and 17 mL/min).",Metabolism of [14C]- and [32P]pyridoxal 5'-phosphate and [3H]pyridoxal administered intravenously to pigs and goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732480/),min,227,241936,DB00114,Pyridoxal Phosphate
,1732480,clearance,"In the goats, [14C] removal was biphasic with T1/2 of 49 and 114 min for 0-30 min and 209 and 227 min for 0.5-6 h (clearance 20 and 17 mL/min).",Metabolism of [14C]- and [32P]pyridoxal 5'-phosphate and [3H]pyridoxal administered intravenously to pigs and goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732480/),[ml] / [min],20,241937,DB00114,Pyridoxal Phosphate
,1732480,clearance,"In the goats, [14C] removal was biphasic with T1/2 of 49 and 114 min for 0-30 min and 209 and 227 min for 0.5-6 h (clearance 20 and 17 mL/min).",Metabolism of [14C]- and [32P]pyridoxal 5'-phosphate and [3H]pyridoxal administered intravenously to pigs and goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732480/),[ml] / [min],17,241938,DB00114,Pyridoxal Phosphate
,1732480,half-life,"Pyridoxal removal from plasma was similar in both species, with a half-life of approximately 12 min from 0-30 min and approximately 50 min for 0.5-3 h.",Metabolism of [14C]- and [32P]pyridoxal 5'-phosphate and [3H]pyridoxal administered intravenously to pigs and goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732480/),min,12,241939,DB00114,Pyridoxal Phosphate
,1732480,half-life,"Pyridoxal removal from plasma was similar in both species, with a half-life of approximately 12 min from 0-30 min and approximately 50 min for 0.5-3 h.",Metabolism of [14C]- and [32P]pyridoxal 5'-phosphate and [3H]pyridoxal administered intravenously to pigs and goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732480/),min,50,241940,DB00114,Pyridoxal Phosphate
,1732480,Clearance,Clearance of [3H]pyridoxal in the four animals ranged from 412 to 2258 mL/min.,Metabolism of [14C]- and [32P]pyridoxal 5'-phosphate and [3H]pyridoxal administered intravenously to pigs and goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732480/),[ml] / [min],412 to 2258,241941,DB00114,Pyridoxal Phosphate
